Reality Check on Ulcerative Colitis
Market access for ulcerative colitis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 69% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In July 2020, the FDA approved Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd.’s Hulio (adalimumab-fkjp) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis. The agency approved the biosimilar of AbbVie Inc.’s Humira (adalimumab) — the sixth one that the agency approved — in both prefilled syringe and auto-injector presentations
- Key Findings: Manufacturers with franchises across indications often hold contracting power and improved position, which is everything in this market. While tumor necrosis factor alpha (TNFa) inhibitors are nearly always the first-line biologic after generics, there are situations where others have been placed on this tier. There’s significant opportunity to contract for position
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.